Enveric Biosciences ENVB Institutional Ownership

Updated Oct 11, 2026

Enveric Biosciences, Inc. (NASDAQ:ENVB) was reported as a holding by 25 institutional investors in 13F filings for the quarter ended June 30, 2026.

• Together they owned 13.31% of the outstanding stock in Q2 2026, up from 2.91% a quarter earlier.
• Total shares held in ENVB rose 865.15% from Q1 2026; the number of holders rose 177.78% from Q2 2025.
• Of these 25 holders, 18 added to their positions, 2 reduced their stakes and 5 left their positions unchanged.
• The aggregate institutional position in Enveric Biosciences was 530.59K shares at the end of Q2 2026, up 475.62K from the prior quarter and up 512.17K from a year earlier.
• As of June 30, 2026, the biggest holder of Enveric Biosciences was Sio Capital Management, LLC with 180K shares, or 4.51% of shares outstanding.
• The largest position increases in ENVB for Q2 2026 were by AdvisorShares Investments LLC (+18.44K shares), Tower Research Capital LLC (+3.88K shares) and SBI Securities Co., Ltd. (+2.59K shares).
• The biggest cuts to ENVB positions during Q2 2026 came from Geode Capital Management, LLC (-20.36K shares) and UBS Group AG (-3.41K shares).
• Per Business Quant, the top 10 investors in ENVB for the quarter ended June 30, 2026 were Sio Capital Management, LLC (180K shares), Ikarian Capital, LLC (100K shares), AdvisorShares Investments LLC (35.42K shares), Renaissance Technologies LLC (32.06K shares), Armistice Capital, LLC (32K shares), Boothbay Fund Management, LLC (30.14K shares), XTX Topco Ltd (18.99K shares), HRT Financial LP (15.46K shares), Vanguard Capital Management LLC (14.91K shares) and Citadel Advisors LLC (13.96K shares).